Jun 28, 2022 Investment from LifeArc, Illumina, and Illumina Ventures will fund genomics startups for Illumina Accelerator Cambridge graduates SAN DIEGO, June 28, 2022 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced its participation in Time Boost Capital I LP, a £30 million genomics venture fund dedicated to... Read more
Jun 22, 2022 New assay brings validated HRD technology from Myriad Genetics to the Illumina TruSight™ Oncology 500, a single, comprehensive pan-cancer test to identify key variants critical for cancer development and progression SAN DIEGO, June 22, 2022 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of a research... Read more
Oct 14, 2021 Ragusa succeeds Hans Bishop, who will continue to serve as Advisor to the CEO through end of 2021 SAN DIEGO, Oct. 14, 2021 /PRNewswire/ — Illumina, Inc. (NASDAQ:ILMN) today announced that Bob Ragusa has been appointed as Chief Executive Officer of GRAIL, a healthcare company whose mission is focused on multi-cancer early detection,... Read more
Sep 30, 2021 Opens Illumina entities in Colombia and México SAN DIEGO, Sept. 30, 2021 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) announced the creation of Illumina Colombia S.A.S. and Illumina México Productos de Biotecnología marking our commitment to expand genomics in Latin America and increase the level of support for our local customers and partners. “Colombia... Read more
Sep 15, 2021 Diverse investments from Israel, Mexico, Poland, South Africa, United Kingdom and United States SAN DIEGO, Sept. 15, 2021 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) has selected seven new genomics companies to join the third global funding cycle of Illumina Accelerator. The global company creation engine, focused on partnering with entrepreneurs to build breakthrough genomics startups,... Read more
Sep 7, 2021 SAN DIEGO, Sept. 7, 2021 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) and Merck (known as MSD outside the United States and Canada) today announced a partnership to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD). Patients whose tumors are HRD-positive may be eligible for... Read more
Aug 3, 2021 SAN DIEGO, Aug. 3, 2021 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) has donated $1 million in sequencing capabilities to the Molecular Diagnostic Reference Laboratory at Kasturba Hospital, in the Municipal Corporate of Greater Mumbai, to help expand SARS-CoV-2 sequencing capabilities in the region and support the broader genomic surveillance effort across India. Kasturba Hospital was... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) today announced that it is appointing Susan Tousi as Chief Commercial Officer (CCO), and Dr. Alex Aravanis as Chief Technology Officer (CTO), Head of Research and Product Development. “We’re fortunate to have Susan and Alex, two of the strongest leaders in the genomics industry, take on these large, important... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) has committed US $60 million in sequencing capabilities to a global pathogen genomics initiative, in partnership with the Bill & Melinda Gates Foundation and other public and private entities. The initiative expands on the Africa Pathogen Genomics Initiative (Africa PGI) announced in October 2020, and will help create a... Read more
SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) (the “Company”) today announced that Jay Flatley has decided to step down from the Board of Directors and John W. Thompson will be appointed as the Company’s new Chair of the Board. These changes will be effective as of the Company’s Annual Shareholder Meeting on May 26, 2021. This... Read more